TY - JOUR
T1 - Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
AU - Masciullo, Valeria
AU - Scambia, Giovanni
AU - Marone, Maria
AU - Gianntelli, Cecilia
AU - Ferrandina, Gabriella
AU - Bellacosa, Alfonso
AU - Panici, Pierluigi Benedetti
AU - Mancuso, Salvatore
PY - 1997
Y1 - 1997
N2 - We analyzed the expression and amplification of cyclin D1 and CDK4 genes in ovarian carcinomas. Northern blot analysis revealed overexpression of cyclin D1 in 12 of 65 (18%) ovarian carcinomas while CDK4 was overexpressed in 7 of 48 cases (14%). None of the tumors showed amplification of any of the 2 genes. Overexpression of cyclin D1 and CDK4 transcripts was correlated, suggesting a role of both genes in altered growth control of ovarian cancer cells. Elevated levels of cyclin D1 were significantly associated with a well-moderately differentiated grade (G1-G2) (p < 0.005). No significant association was found between cyclin D1 expression and estrogen receptor, progesterone and epidermal growth factor receptor content. Cyclin D1 expression does not appear to be associated with clinical outcome in human ovarian cancer, although a longer follow-up period and screening of other molecules involved in the same pathway would be necessary to assess this hypothesis.
AB - We analyzed the expression and amplification of cyclin D1 and CDK4 genes in ovarian carcinomas. Northern blot analysis revealed overexpression of cyclin D1 in 12 of 65 (18%) ovarian carcinomas while CDK4 was overexpressed in 7 of 48 cases (14%). None of the tumors showed amplification of any of the 2 genes. Overexpression of cyclin D1 and CDK4 transcripts was correlated, suggesting a role of both genes in altered growth control of ovarian cancer cells. Elevated levels of cyclin D1 were significantly associated with a well-moderately differentiated grade (G1-G2) (p < 0.005). No significant association was found between cyclin D1 expression and estrogen receptor, progesterone and epidermal growth factor receptor content. Cyclin D1 expression does not appear to be associated with clinical outcome in human ovarian cancer, although a longer follow-up period and screening of other molecules involved in the same pathway would be necessary to assess this hypothesis.
KW - Age Factors
KW - Biomarkers, Tumor/analysis
KW - Cyclin D1
KW - Cyclin-Dependent Kinase 4
KW - Cyclin-Dependent Kinases/analysis
KW - Cyclins/analysis
KW - Disease Progression
KW - Epithelium/metabolism
KW - ErbB Receptors/analysis
KW - Female
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Middle Aged
KW - Neoplasm Staging
KW - Oncogene Proteins/analysis
KW - Ovarian Neoplasms/drug therapy
KW - Predictive Value of Tests
KW - Proto-Oncogene Proteins
KW - Receptors, Estrogen/analysis
KW - Receptors, Progesterone/analysis
KW - Recurrence
KW - Regression Analysis
KW - Statistics, Nonparametric
KW - Tumor Cells, Cultured
UR - http://www.scopus.com/inward/record.url?scp=0030768570&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1997XU12400005&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q
DO - 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q
M3 - Article
C2 - 9291427
SN - 0020-7136
VL - 74
SP - 390
EP - 395
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 4
ER -